<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00918554</url>
  </required_header>
  <id_info>
    <org_study_id>P070140</org_study_id>
    <nct_id>NCT00918554</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Methotrexate to Treat Sarcoid-associated Uveitis</brief_title>
  <acronym>UVEXATE</acronym>
  <official_title>Corticosteroid Sparing Effect of Methotrexate in Patients With Sarcoid- Associated Uveitis: A Double Blind, Randomized, Placebo Controlled-study -UVEXATE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether methotrexate is a effective corticosteroid
      sparing agent in the treatment of sarcoid-associated uveitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Macular oedema remains a significant cause of blindness. Corticosteroids are effective in the
      treatment of sarcoid-associated macular oedema but more than 50% of relapses occur when
      corticosteroids are tapered. Methotrexate (MTX) at low dose has been shown to be an effective
      and safe steroid-sparing agent for lung sarcoidosis and compilation of reported small series
      of patients with sarcoid-associated uveitis suggest that only 25% of relapses could be
      achieved with low dose MTX. We decide therefore to test the clinical efficacy of MTX in
      sarcoid-associated uveitis.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    insufficient number of inclusion
  </why_stopped>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of macular oedema relapses. Every two weeks for five months, the amount of macular oedema will be assessed by Optical Coherence Tomography.</measure>
    <time_frame>at 26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulated dose of prednisone</measure>
    <time_frame>at 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of triamcinolone injections</measure>
    <time_frame>at 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>at 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with best corrected visual acuity under 0.1, 0.2 and 0.</measure>
    <time_frame>at 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with active anterior and /or posterior uveitis</measure>
    <time_frame>at 26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Sarcoid-associated Uveitis</condition>
  <condition>Ocular Sarcoidosis</condition>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>Methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>All patients will receive three pulses of methylprednisolone (5 mg/kg) followed by four weeks of prednisone (1 mg/kg daily). After randomization, patients will receive either prednisone (1 mg/kg daily) plus methotrexate (0.3 mg/kg weekly) or prednisone (1 mg/kg daily) plus placebo. Therapies will be administered orally. Corticosteroids will be progressively tapered when macular oedema completely resolve. Unilateral macular oedema relapses will be treated with a single local injection triamcinolone acetonide. Increasing dose of prednisone will be administered in case of bilateral macular oedema relapses.</description>
    <arm_group_label>Methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>All patients will receive three pulses of methylprednisolone (5 mg/kg) followed by four weeks of prednisone (1 mg/kg daily). After randomization, patients will receive either prednisone (1 mg/kg daily) plus methotrexate (0.3 mg/kg weekly) or prednisone (1 mg/kg daily) plus placebo. Therapies will be administered orally. Corticosteroids will be progressively tapered when macular oedema completely resolve. Unilateral macular oedema relapses will be treated with a single local injection of triamcinolone acetonide. Increasing dose of prednisone will be administered in case of bilateral macular oedema relapses.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 18 years old

          -  Provided written consent for participation in the trial prior to any study-specific
             procedures or requirements

          -  Posterior uveitis or panuveitis associated with macular oedema defined as increased
             macular thickness (more than 250 mm assessed by Stratus TD-OCT or 300 mm with Cirrus
             SD-OCT ) and/or the presence of cystoid spaces in the macula, and the absence of
             epiretinal membranes.

          -  Patient with oral contraception

          -  Posterior uveitis or panuveitis associated with macular oedema

          -  Patients with histologically proven sarcoidosis or a presumed sarcoidosis. In case of
             a non caseating granuloma in biopsy tissues, the patients with presumed sarcoidosis
             meet at least 2 of the 4 following criteria: typical changes on chest radiography and
             computed tomography; predominantly CD4 lymphocytosis in bronchoalveolar lavage (BAL)
             fluid; elevated serum ACE levels; elevated gallium or 5 fluorodeoxyglucose uptake

        Exclusion Criteria:

          -  Patients who do not fulfill the inclusion criteria

          -  Other causes of uveitis

          -  Extra ophthalmologic manifestations of sarcoidosis justifying corticosteroids

          -  Patients previously treated with immunosuppressive agents or corticosteroids of more
             than 10 mg daily over 15 days.

          -  Patients with life-threatening conditions

          -  Chronic hepatopathy or renal failure

          -  Uncontrolled diabetes mellitus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sébastien ABAD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Avicenne - Service de Médecine Interne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Michallon de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2009</study_first_submitted>
  <study_first_submitted_qc>June 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2009</study_first_posted>
  <last_update_submitted>May 30, 2014</last_update_submitted>
  <last_update_submitted_qc>May 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sarcoid-associated uveitis</keyword>
  <keyword>Macular oedema</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Conventional corticosteroids sparing agent.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

